Authors
Pradeep Kumar, Emmanuelle Merquiol, Talya Avraham, Reut Sinai-Turyanski, Pankaj K Singh, Roberto A Ribas, Sahar Sweetat, Uri Sprecher, Noam Muchtar, Manjeet Gupta, Kumudesh Mishra, Shashank Kumar Ojha, Zhanna Yekhtin, Hava Glickstein, Ori Shalev, Alexandra Eliassaf, Anna Morshina, Hadas Segev-Yekutiel, Sharon Garti, Nissim Garti, Hannah Rosenmann, Miguel Weil, Matthew S Gentry, Galia Blum, Or Kakhlon
Published in
Life science alliance. Volume 9. Issue 12. Epub Oct 07, 2026.
Abstract
Mucopolysaccharidosis type I (MPS-I) is a hereditary lysosomal storage disorder caused by deficiency in the lysosomal enzyme α-L-iduronidase (IDUA) leading to pathogenic over-accumulation of glycosaminoglycans (GAGs), major constituent of connective tissue and mediators of cell signaling. We tested the therapeutic efficacy of the autolysosomal activator GHF201 in the Idua -/- mouse model of MPS-I. We show that GHF201 reduced GAGs and increased cathepsin activity in Idua -/- mouse embryonic fibroblasts (MEFs) and brain cells. In vivo GHF201 improved aberrant locomotion and behavior, reduced interstitial cathepsins in joints and liver, increased systemic catabolism, corrected bone dysplasia, increased autophagic flux, and ameliorated CNS neurodegeneration and neuroinflammation. GHF201 also reduced brain N-glycans, which are degraded in lysosomes. In conclusion, the lysosomal and autophagic activator GHF201 was demonstrated to improve various pathophysiological parameters in MPS-I-modeling Idua -/- female mice. Our results suggest that GHF201 can complement the inadequate Aldurazyme enzyme replacement therapy as an add-on therapy.
PMID:
42843973
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 20
- Comments 0